ENSC - Ensysce Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
La Jolla,
United States
Type: Equity
ENSC price evolution
ENSC
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1.78 | $0.22 | $0.1 | $0.1 |
| Inventory | ||||
| Total current assets | $9.09 | $2.46 | $4.7 | $2.29 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $9.38 | $2.8 | $5.07 | $2.71 |
| Current liabilities | ||||
| Accounts payable | $1.97 | $0.48 | $0.98 | $1.94 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2.8 | $1.31 | $1.64 | $3.33 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2.48 | $0.99 | $1.33 | $3.03 |
| Shareholders' equity | ||||
| Retained earnings | -$125.98 | -$126.64 | -$124.67 | -$121.56 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.05 | |||
| Short term investments | ||||
| Net receivables | $0.1 | $0.28 | $0.44 | $0.02 |
| Inventory | ||||
| Total current assets | $2.29 | $5.3 | $15.66 | $0.23 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.63 | |||
| Total investments | ||||
| Total assets | $2.71 | $5.89 | $16.42 | $12.85 |
| Current liabilities | ||||
| Accounts payable | $1.94 | $2.94 | $0.3 | $0.26 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.33 | $9.46 | $16.48 | $0.26 |
| Long term debt | $0.14 | $4.44 | $0.79 | |
| Total noncurrent liabilities | $13.8 | |||
| Total debt | ||||
| Total liabilities | $3.03 | $9.6 | $24.3 | $14.06 |
| Shareholders' equity | ||||
| Retained earnings | -$121.56 | -$110.93 | -$85.85 | -$1.21 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.42 | $0.18 | $0.31 | $0.52 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $2.77 | $2.14 | $2.15 | $3.67 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0 | -$0.03 | -$1.25 | -$0.34 |
| Net income | ||||
| Net income | $0.66 | -$1.97 | -$3.12 | -$3.5 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.23 | $2.52 | $3.53 | |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $12.95 | $26.75 | $23.4 | $1.37 |
| Operating income | -$1.37 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.24 | |||
| Interest expense | -$0.35 | -$0.11 | -$0.62 | |
| Net income | ||||
| Net income | -$10.63 | -$25.09 | -$29.08 | $4.31 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $9.77 | $6.12 | $5.69 | $8.76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $3.03 | -$0.08 | $2.28 | -$2.02 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | $4.31 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.86 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $183.4 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $8.76 | $8.77 | $20.31 | -$183.55 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.02 | -$9.12 | $12.07 | -$1.01 |
News
Fundamentals
| Market cap | $30.24M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 13.87M |
| Revenue | $4.42M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$7.93M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -3.81 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.84 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.57 |
|---|---|
| ROA | -158.84% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.24 |
| Quick ratio | N/A |